A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390, a PI3K/mTOR Dual Inhibitor, for the Treatment of Advanced Solid Tumors With PIK3CA Mutations
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- Safety of WX390 in treating patients with advanced malignant solid tumors harboring PIK3CA mutations.
研究概览
简要总结
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 in patients with advanced solid tumors. The main question it aims to answer is:
• safety and preliminary efficacy in WX390 therapy. Participants will be treated with WX390 orally and follow the efficacy and safety evaluation according to the protocol.
详细描述
This study is a multicenter, open-label phase Ib/IIa clinical trial for patients with advanced solid tumors who have failed standard treatment. The study adopts a basket design, divided into 6 cohorts, with a total of 70-80 advanced solid tumor patients with PIK3CA mutations enrolled. Participants will receive WX390 treatment administered continuously daily, with each cycle lasting 28 days, until disease progression or intolerable toxicity occurs. During the study, safety and efficacy will be evaluated, with efficacy assessment based on RECIST 1.1. In addition, the study will collect tumor tissue or blood samples from the participants to explore the relationship between other biomarkers and treatment efficacy, as well as the impact of changes in PIK3CA mutation status before and after treatment on efficacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-75 years of age
- •Histologically or cytologically confirmed advanced malignant solid tumors (excluding non-small cell lung cancer) who have failed standard treatment, have no standard treatment options, or for whom standard treatment is not suitable at the current stage (colorectal cancer patients must provide genetic test results confirming KRAS wild-type)
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •Life expectancy of more than 3 months
- •At least one measurable lesion according to RECIST 1.1
- •Adequate organic function
- •Signed and dated informed consent
排除标准
- •Anti-tumor treatments such as chemotherapy, radiotherapy, biological therapy, endocrine therapy, or immunotherapy received within 4 weeks before the first use of the study drug
- •Other unapproved clinical trial drugs or treatments received within 4 weeks before the first use of the study drug
- •Major organ surgery (excluding biopsy) or significant trauma within 4 weeks before the first use of the study drug
- •Systemic use of corticosteroids or other immunosuppressive agents within 14 days before the first use of the study drug
- •Previous treatment with PI3K, AKT, or mTOR inhibitors
- •Active infection requiring systemic anti-infection treatment
- •Known alcohol or drug dependence
- •Individuals with mental disorders or poor compliance
- •Pregnant or lactating women
- •The researcher believes that the subject has other serious systemic medical history or other reasons that make them unsuitable for participating in this clinical study
研究组 & 干预措施
WX390
Participants will receive WX390 continuous oral dosing (1.1 mg once a day).
干预措施: WX390 (Drug)
结局指标
主要结局
Safety of WX390 in treating patients with advanced malignant solid tumors harboring PIK3CA mutations.
时间窗: From the start of the trial,up to 24 weeks
Safety will be evaluated by monitoring AE/SAE
Objective Response Rate (ORR)
时间窗: From the start of the trial,up to 24 weeks
ORR is defined as the proportion of patients with complete response (CR) and partial response (PR) according to RECIST 1.1.
次要结局
- Disease Control Rate (DCR) determined according to RECIST 1.1 criteria(From the start of the trial,up to 24 weeks)
- Duration of Response (DOR) determined according to RECIST 1.1 criteria(From the start of the trial,up to 24 weeks)
- Progression-Free Survival (PFS) determined according to RECIST 1.1 criteria(From the start of the trial,up to 24 weeks)